Chartwell Investment Partners LLC lessened its stake in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 43.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 51,147 shares of the life sciences company’s stock after selling 39,478 shares during the period. Chartwell Investment Partners LLC’s holdings in Integra Lifesciences were worth $2,448,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in the company. State Street Corp lifted its position in shares of Integra Lifesciences by 5.2% during the 2nd quarter. State Street Corp now owns 1,575,125 shares of the life sciences company’s stock valued at $85,860,000 after acquiring an additional 78,082 shares during the last quarter. Orbimed Advisors LLC lifted its position in shares of Integra Lifesciences by 155.5% during the 3rd quarter. Orbimed Advisors LLC now owns 1,090,910 shares of the life sciences company’s stock valued at $55,069,000 after acquiring an additional 664,000 shares during the last quarter. Jennison Associates LLC lifted its position in shares of Integra Lifesciences by 48.3% during the 3rd quarter. Jennison Associates LLC now owns 1,034,702 shares of the life sciences company’s stock valued at $52,232,000 after acquiring an additional 336,930 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Integra Lifesciences by 7.8% in the fourth quarter. Wells Fargo & Company MN now owns 869,537 shares of the life sciences company’s stock valued at $41,616,000 after purchasing an additional 63,204 shares in the last quarter. Finally, Westfield Capital Management Co. LP lifted its holdings in shares of Integra Lifesciences by 5.8% in the third quarter. Westfield Capital Management Co. LP now owns 840,556 shares of the life sciences company’s stock valued at $42,431,000 after purchasing an additional 45,840 shares in the last quarter. Institutional investors own 86.39% of the company’s stock.
Shares of Integra Lifesciences Holdings Corp (IART) opened at $52.26 on Tuesday. The company has a quick ratio of 3.39, a current ratio of 4.49 and a debt-to-equity ratio of 1.26. Integra Lifesciences Holdings Corp has a 1-year low of $40.51 and a 1-year high of $56.42. The stock has a market capitalization of $4,100.00, a price-to-earnings ratio of 85.67, a PEG ratio of 1.67 and a beta of 0.67.
A number of research firms have recently issued reports on IART. TheStreet upgraded Integra Lifesciences from a “c+” rating to a “b-” rating in a report on Wednesday, February 7th. BidaskClub upgraded Integra Lifesciences from a “strong sell” rating to a “sell” rating in a report on Monday, February 5th. Oppenheimer restated a “buy” rating on shares of Integra Lifesciences in a report on Thursday, January 11th. Barclays restated a “hold” rating and issued a $53.00 target price on shares of Integra Lifesciences in a report on Tuesday, January 9th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $52.00 target price on shares of Integra Lifesciences in a report on Friday, January 5th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $52.70.
ILLEGAL ACTIVITY WARNING: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/20/chartwell-investment-partners-llc-sells-39478-shares-of-integra-lifesciences-holdings-corp-iart.html.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.